Skip to Content

Cormedix Inc CRMD

Morningstar Rating
$4.78 −0.13 (2.65%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CRMD is trading at a 376% premium.
Price
$4.80
Fair Value
$3.28
Uncertainty
Extreme
1-Star Price
$76.22
5-Star Price
$8.32
Economic Moat
Xvqy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRMD is a good fit for your portfolio.

Trading Information

Previous Close Price
$4.91
Day Range
$4.735.04
52-Week Range
$2.577.00
Bid/Ask
$4.71 / $4.90
Market Cap
$262.71 Mil
Volume/Avg
552,954 / 599,202

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
82

Comparables

Valuation

Metric
CRMD
EWTX
SLRN
Price/Earnings (Normalized)
Price/Book Value
4.533.910.87
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
CRMD
EWTX
SLRN
Quick Ratio
6.1436.4913.08
Current Ratio
6.6537.0813.27
Interest Coverage
−1,546.89
Quick Ratio
CRMD
EWTX
SLRN

Profitability

Metric
CRMD
EWTX
SLRN
Return on Assets (Normalized)
−62.43%−23.18%−28.15%
Return on Equity (Normalized)
−71.06%−24.45%−35.30%
Return on Invested Capital (Normalized)
−74.95%−28.92%−41.97%
Return on Assets
CRMD
EWTX
SLRN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
WzzlzcfcywRhgk$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
QqwmzwzMqvsnjk$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
WhtvdwjwPxptdnp$121.2 Bil
Moderna Inc
MRNA
VblhctnqNlvn$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
DdyyxhbqHxyggf$33.0 Bil
argenx SE ADR
ARGX
HkcdjcjfMfr$27.9 Bil
BioNTech SE ADR
BNTX
LztkrqgkhTdyph$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
JltqlyjpLdngt$16.1 Bil
United Therapeutics Corp
UTHR
LbklwcrvkNqhjn$14.3 Bil
Incyte Corp
INCY
QmfstcdtNhzflq$12.5 Bil

Sponsor Center